20 Oct 2015 14:23
Immunodiagnostic Systems Holdings plc
Board Appointment
20 October 2015
Immunodiagnostic Systems Holdings plc ("IDS" or "the Company" or "the Group"), a leading solution provider to the clinical laboratory diagnostic market, is pleased to announce that Klaus Peter Kaspar, aged 63, will join the Board of IDS as a Non-Executive Director with effect from 1 November 2015.
Peter has over 35 years' experience in life sciences and diagnostics. From 2005 to 2011, Peter was Head of the Microbiology unit and Head of Global Research and Development at bioMérieux S.A., a world leader in the field of in-vitro diagnostics. Prior to bioMerieux, he spent a significant part of his career with Roche Diagnostics (formerly Boehringer Mannheim GmbH) in Europe, Latin-America and the US, in various positions in Strategy, Business Development and R&D Management. He holds a PhD in biochemistry from the University of Münster.
Burkhard Wittek, Non-Executive Chairman of IDS said: "Peter brings to IDS significant experience in the field of in-vitro diagnostics gained within some leading groups in the industry. He combines a deep understanding of the technology with a very good business sense. The board of IDS looks forward to capitalising on this, in particular accelerating the development of new menu and making our manufacturing more efficient."
The following information is disclosed pursuant to Schedule Two paragraph (g) of the AIM Rules for Companies:
Current Directorships and Partnerships:
Daktari Diagnostics, Inc.
Magellan bioConsult UG
Previous Directorships and Partnerships in last five years:
bioMerieux S.A.
bioMerieux BV
bioMerieux P Ltd.
There are no other disclosures required in relation to Rule 17 or paragraph (g) of Schedule 2 of the AIM Rules for Companies.
For further information:
Immunodiagnostic Systems Holdings plc
Tel : +44 (0)191 519 0660
Patricio Lacalle, Chief Executive Officer
Peel Hunt LLP
Tel : +44 (0)207 418 8900
James Steel
Oliver Jackson
About Immunodiagnostic Systems Holdings PLC:
The Group's vision is to be a leading solution provider to the clinical laboratory diagnostic market. IDS's strategy is focused on developing, internally and through partnership, its automated assay menu for its proprietary automated immunoassay analyser, the IDS-iSYS system. Internally the Group is focused on developing an endocrinology excellence menu and externally IDS works with partners to develop assay panels in complementary indication fields. The Group sells its products primarily in the clinical laboratory market across a range of customers from reference laboratories to physician office laboratories. IDS has field sales forces in certain European countries, including France and Germany, the United States and Brazil and works with distributors in other markets including China, Italy and Spain.